Subscribe to The Value Anchor Topic / The Trend Catcher Topic —unlock the full historical archive and never miss a weekly pick again.

Alphabet's (Alphabet Inc. Class C(GOOG.US) / Alphabet Inc. Class A(GOOGL.US) ) latest 13F shows approximately 551 million Class A shares of SpaceX(SPCX.US) with a reported market value of $94.18 billion — accounting for 95.05% of the entire filing. At first glance, it looks like Google dumped nearly all of its investable capital into Elon Musk's rocket company in a single quarter.

It didn't. SpaceX listed on Nasdaq on June 12. Google had been an investor for over a decade. What happened in Q2 was not a purchase but a reclassification: a long-held private stake converted into publicly traded shares and, for the first time, entered the 13F reporting window. The $94 billion figure reflects the market's revaluation of a position Google has held since the early days — not a new directional bet.

Think of it as turning on a light in a room that was always full of furniture. Nothing was moved in; it just became visible.

Almost none of it is liquid

Google's Q2 earnings disclosure reveals that roughly $80 billion of its SpaceX shares are under short-term sale restrictions, with an additional ~$14.1 billion locked up through Q3 2027. In practice, nearly the entire position is frozen — it carries a public-market price tag but cannot be freely converted to cash anytime soon.

Strip out SpaceX, and Q2 was quiet

Excluding SpaceX, Google's 13F portfolio stood at roughly $4.91 billion, up about 22% from $4.02 billion in Q1. But most of that gain came from share-price appreciation and two more private-to-public conversions rather than active buying:

• Parabilis Medicines, Inc.(PBLS.US) — ~$135 million at quarter-end. The company IPO'd on June 10; Google/GV was a pre-IPO investor.
• Fervo Energy Company Class A(FRVO.US) — ~$51.5 million. IPO'd on May 13; same story.

The only clear active trading was on the sell side. Google trimmed or exited several biotech names:

• Revolution Medicines(RVMD.US): reduced ~346K shares
• Monte Rosa Therapeutics, Inc.(GLUE.US) : reduced ~312K shares
• Relay Therapeutics, Inc.(RLAY.US): reduced ~154K shares
• Ethos Technologies(LIFE.US): reduced ~148K shares
• Tenaya Therapeutics, Inc.(TNYA.US): full exit, ~916K shares sold

The pattern is consistent: Google continued pulling back from early-stage life-science bets, while its apparent new positions were simply old venture stakes surfacing after IPOs.

A "space fund" — on paper?

Combine SpaceX(SPCX.US), Planet Labs PBC(PL.US) and AST SPACEMOBILE INC(ASTS.US), and space-related names account for 97.03% of Google's 13F. But neither PL nor ASTS saw any change in share count during Q2 — Google did not chase other space stocks after SpaceX's listing. The concentration is a mathematical artifact: one position grew so large it dwarfed everything else.

Still, the fact that all three sit at the top of the filing is not an accident. It reflects Google's long-running strategic interest in satellite internet, Earth observation and space-based connectivity — themes that dovetail with its cloud and AI infrastructure ambitions.

What Google's portfolio actually looks like without the distortion

Once you adjust for SpaceX's outsized weight, the investment thesis is straightforward and closely aligned with Google's core business:

• AI compute & chip architecture: Arm Holdings(ARM.US)
• Data-center energy: Fervo Energy Company Class A(FRVO.US)
• AI healthcare: Tempus Al(TEM.US)
• Enterprise software & automation: Freshworks, Inc. Class A(FRSH.US), GITLAB INC.(GTLB.US), UiPath(PATH.US) 

The portfolio orbits compute, energy, connectivity, enterprise software and life sciences — all areas with clear synergies to Google's AI and cloud strategy.

Three things that actually matter going forward

1. What happens when the lock-ups lift. Will Google hold SpaceX for the long term, or gradually monetize and redeploy capital into AI infrastructure? The choice will shape both GOOG's balance-sheet narrative and SPCX's post-lock-up supply dynamics.

2. How much SpaceX moves Google's earnings. With a ~$94 billion mark-to-market position, even modest swings in SPCX's stock price will amplify quarterly profit volatility for Alphabet — potentially obscuring the trajectory of search, cloud and AI operating income.

3. Core operating profit ex-investments. Strip out equity-investment gains, and investors need to see whether Google's search, cloud and AI businesses can sustain profit growth on their own merits.

The signal, not the noise

This 13F's real story is not "Google poured $94 billion into SpaceX last quarter." It is that a decade-old venture bet — one that predates most of the current AI hype cycle — has finally been marked to market and made public. The surface reads like a concentrated space fund; the substance is a masterclass in patient, early-stage capital allocation that just happened to crystallize in a single filing.

Disclaimer: For informational purposes only; not investment advice. Data sourced from SEC 13F filings as of Q2 2026.